Compare Ginkgo Bioworks Holdings Inc (DNA) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs General Dynamics Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while General Dynamics Corporation trades at $392 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 209.7× Ginkgo Bioworks Holdings Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | GD | |
|---|---|---|
Market Cap | $505.73M | $106.03B |
Sector | Health | Industrials |
52-Week High | $16.14 | $395.97 |
52-Week Low | $5.48 | $312.53 |
Enterprise Value | $607.68M | $111.17B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
General Dynamics (GD) trades at $394.17, down 0.45% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating estimates, revenue growth to $52.55B in 2025, and improving profit margins. Recent contract wins include a $29.5B submarine award and a $1.3B Army cybersecurity contract, supporting the $136.5B backlog.
Outlook remains positive with analyst consensus target of $427.40 representing 8.4% upside potential. Key opportunities include defense budget tailwinds and strong contract pipeline, while risks involve valuation concerns at 23.9 P/E and execution challenges on large government contracts. The stock offers steady dividend payments with recent $1.59 quarterly declaration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
